GlassScriptPhysician profile
Edson Deguzman
NPI 1174512198
$885.49
in general payments reported to CMS, 2019-2025
14 companies · $109 in 2025
The $109 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $110 · 2020: $63.33 · 2021: $163 · 2022: $100 · 2023: $195 · 2024: $145 · 2025: $109.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $449.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $448.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $225.81 | 2019-2025 | |
| Baxter Healthcare | $113.66 | 2023-2025 | Hillrom - Carnation Ambulatory Monitor |
| Janssen Pharmaceuticals, INC | $87.14 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $82.72 | 2021-2023 | |
| Amgen INC. | $77.87 | 2021-2025 | Repatha |
| Boston Scientific Corporation | $59.76 | 2025 | Cds - Mct/Cem Monitoring, Watchman Flx |
| Irhythm Technologies, INC. | $55.14 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $40.26 | 2019-2021 | |
| Novo Nordisk INC | $36.54 | 2023-2024 | Ozempic, Rybelsus |
| Edwards Lifesciences Corporation | $28.70 | 2020-2023 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Kiniksa Pharmaceuticals International, Plc | $22.98 | 2024 | Arcalyst |
| Vifor Pharma, INC. | $21.09 | 2021 | |
| Esperion Therapeutics, INC. | $17.97 | 2024 | Nexletol |
| Astrazeneca Pharmaceuticals LP | $15.85 | 2024 | Farxiga |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Edson Deguzman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.